On November 2, Alnylam Pharmaceuticals fell 5.03% in Regular Trading, trading at $156.845 per share, with turnover of $159 million.
The move followed continued market digestion of near-term risk tied to potential changes in the 340B reimbursement framework for Amvuttra, a development that analysts said could weigh on hospital-channel utilization starting in 2027.
Recent company updates added to the pressure. Alnylam reported third-quarter revenue of $1.46 billion, above the $1.43 billion consensus, and adjusted EPS of $16.26, while maintaining total net product revenue guidance at $4.70 billion to $5.10 billion. However, analysts noted TTR revenue is now expected toward the low end of guidance, Amvuttra sales were roughly in line, and part of the quarter benefited from favorable inventory dynamics and a one-time gross-to-net adjustment. Some analysts still argued the selloff appeared overdone given continued execution potential and a large untreated patient population.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments